Your session is about to expire
← Back to Search
Local Anesthetic
Liposomal Bupivacaine Interscalene brachial plexus (ISB) for Shoulder Replacement Surgery
Phase 4
Waitlist Available
Led By Doug Jaffe, DO
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 48 hours
Awards & highlights
Study Summary
This study is evaluating whether the use of plain bupivacaine with common adjuvants for interscalene block (ISB) provides non-inferior analgesic results compared to the use of liposomal bupivacaine for ISB, in patients undergoing total shoulder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 48 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 48 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Average Pain Scores for the First 48 Hours
Secondary outcome measures
Postoperative Opioid Consumption for the First 48 Hours
Satisfaction With Surgical Experience
Trial Design
2Treatment groups
Active Control
Group I: Liposomal Bupivacaine Interscalene brachial plexus (ISB)Active Control1 Intervention
Group II: Bupivacaine with adjuvants ISBActive Control1 Intervention
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,241 Previous Clinical Trials
1,004,212 Total Patients Enrolled
Doug Jaffe, DOPrincipal InvestigatorWake Forest University Health Sciences
1 Previous Clinical Trials
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger